Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MALVERN, Pa., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that the Company received a letter from the Listing Qualification Department of The NASDAQ Capital Market (“Nasdaq”) notifying that Ocugen has been granted an additional 180-day compliance period or until March 8, 2021, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2) (the “Rule”).

Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Because of the dynamics of the new normal, troubled names like OCGN stock continue to attract speculative interest. Perhaps some math will finally dissuade these gamblers?

The Math Simply Doesn’t Favor Ocugen Stock

While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success.
The post For Biopharma Ocugen, Think Speculation In Small Doses appeared first on InvestorPlace.

For Biopharma Ocugen, Think Speculation In Small Doses

MALVERN, Pa., Sept.  03, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 3 p.m. ET.

Ocugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Ocugen is raising cash through its orphan drug designation, but it still faces risks. Make sure you treat OCGN stock as a speculation.

Make Sure You Understand the Risks Before Speculating on Ocugen Stock

OCGN stock has held up despite the failure of what was its flagship drug. The remaining pipeline simply isn't strong enough for investors to risk more capital.

Ocugen Needs Too Much Time and Too Much Cash

Until we begin to see solid trial results, OCGN stock could easily plunge back to 20 cents a share. Avoid investing in Ocugen for now.

It’s Best to Avoid Ocugen Stock at the Moment

MALVERN, Pa., Aug.  28, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the  LD 500 Virtual Investor Conference  on Friday, September 4 at 11 a.m. ET.

Ocugen to Present at the LD 500 Virtual Investor Conference

There's a good deal of downside risk, but Ocugen is worth a look. OCGN stock is likely to fall as Ocugen raises $30 million or 54% of its equity to fund operations over the next 2 plus years.

Ocugen Stock Looks Like a Really Good Short Candidate Here

Recent news helps the odds for OCGN stock, but speculators have gotten carried away. Don't waste your time (or risk your capital) with this.

Don’t Waste Your Time With Long-Shot Penny Stock Ocugen

Ocugen has no revenue and is years away from developing a product. While the cause of developing therapies to fight blindness is laudable, there's no money to be made with OCGN stock.

There’s No Money to Be Made From Buying Ocugen Stock

Ocugen got good news Aug. 14 announcing a fourth orphan drug designation for its ophthalmology gene therapy.

There’s a Reason Why Ocugen Is a Last Resort in Eye Care

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q2 2020 Results - Earnings Call Transcript

OCGN stock has been a hot penny stock. But no revenue and a lead candidate that is years away, are reminders that Ocugen is still a penny stock.

Be Sure You’re Clearly Seeing What’s Happening at Ocugen

Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program

Ocugen Provides Business Update and Second Quarter 2020 Financial Results

Some red-hot penny stocks are worth chasing; OCGN stock is not one of them. In fact, this rally is worth fading.

Execution Challenges Could Short-Circuit the Big Ocugen Stock Rally

The FDA just gave a special designation to one of Ocugen's flagship products. That is good for science and it's great for OCGN stock.

A New Orphan Drug Designation Gives Hope to Ocugen Stock

Initially, the stupendous rise of OCGN stock may give you the case of the FOMOs. But don’t let that emotions guide you as Ocugen is driven by completely irrational actors.

Ocugen Investors Are Missing the Obvious Signs of Failure

Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases

Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

Ocugen got a crucial piece of good news from the FDA. But with the company's lead drug years from approval, OCGN stock remains speculative.

What’s Next For Ocugen After Scoring Orphan Drug Status

Ocugen just doesn't have the qualities that make it attractive to me. Particularly under a buck, OCGN stock is one to avoid.

There Are So Many Stocks to Buy — Ocugen Isn’t One of Them

MALVERN, Pa., Aug.  06, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will host a conference call to discuss its Q2 2020 financial results and provide a business update at 8:30 a.m. on Friday, August 14, 2020.

Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

OCGN stock offers risky odds with a limited payoff structure. Stay away from Ocugen except for a speculative play.

Long-Term Investors May Want to Keep Away from Ocugen

Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Degenerative diseases (IRDs) Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Degenerative diseases (IRDs)

Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

MALVERN, Pa., July  21, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug Congress USA 2020 Conference, to be held virtually from August 24-27, 2020.

News for Ocugen, Inc. Stock (OCGN)